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Vitamin C improves resistance but not conduit artery endothe- Atherosclerosis is the major cause of morbidity and
lial function in patients with chronic renal failure. mortality in patients with renal disease, with a markedly
Background. Chronic renal failure is associated with im- increased cardiovascular risk in dialysis patients com-
paired endothelium-dependent vasodilation and accelerated
pared with similar patients with normal renal functionatherogenesis. To examine whether endogenous reactive oxy-
[1]. While the prevalence of established cardiovasculargen species (ROS) modify endothelial function in renal failure,
risk factors is high in patients with renal disease [2], ad-we evaluated the effect of the antioxidant vitamin C on endo-
thelium-dependent responses in both the conduit and resis- ditional pathogenic mechanisms related to uremia make
tance vasculature of subjects with severe renal impairment. significant contributions to atherogenesis in this group.
Methods. Endothelial function of the forearm resistance vas- Oxidative stress has been implicated in the pathogene-
culature was assessed using plethysmography to measure the
sis of atherosclerosis associated with traditional cardio-dilator response to intra-arterial acetylcholine (Ach) (25 to 100
vascular risk factors [3–10]. Oxidative stress results fromnmol/min). Endothelial function of radial and brachial arteries
the production of reactive oxygen species (ROS), whichwas assessed using vascular ultrasound to measure the dilator
response to flow during reactive hyperemia [flow-mediated include superoxide, hydrogen peroxide, and hydroxyl
dilatation (FMD)]. Studies were performed before and after radicals. ROS may contribute to many of the pathogenic
administration of vitamin C by intra-arterial infusion (25 mg/ mechanisms of atherosclerosis by causing endothelial
min) in 33 predialysis patients or by intravenous infusion (3 g)
damage, smooth muscle proliferation, and immune cellin 17 hemodialysis patients.
activation [11]. In patients with atherosclerosis, there isResults. Parenteral administration of vitamin C resulted in a
biochemical evidence to suggest that there is increased100-fold increase (intra-arterial studies) and a 4.5-fold increase
(intravenous studies) in serum antioxidant activity. Vitamin oxidative stress, which results from an altered balance
C administration increased the dilator response to ACh in of endogenous pro- and antioxidants. These biochemical
resistance vessels (P  0.01), but did not alter the dilator markers are accentuated in uremia, consistent with a role
response to flow in conduit vessels of either dialysis (P 
for ROS in the vasculopathy of renal disease [12]. Oxida-0.3) or predialysis subjects (P  0.8). In the presence of the
tive stress may cause endothelial dysfunction throughnitric oxide (NO) synthase inhibitor NGmonomethyl-l-arginine
inactivation of endothelium-derived vasodilators [such(L-NMMA), there was no effect of vitamin C on resistance
vessel endothelial function. In all cases the dilator response as nitric oxide (NO)] that are known to have atheropro-
to the endothelium-independent dilators was unaffected by tective properties. The effect of antioxidants on endothe-
vitamin C. lium-dependent dilatation has been used to assess the
Conclusion. Acute administration of vitamin C reduces oxi-
consequences of oxidative stress on vascular function. Indant stress in renal failure and improves NO-mediated resis-
support of this strategy, vitamin C improves endothelialtance vessel dilatation.
dilator function in patients at risk of atherosclerosis [3–5,
13]. Similarly, antioxidant treatment has been shown to
improve endothelial function in renal transplant recipi-Key words: renal failure, endothelial function, atherosclerosis, antioxi-
dants, vitamin C. ents [14] and to reduce overall mortality in patients with
renal failure [15].
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vitamin C parenterally to patients with renal failure, 2 cm segment was determined for each image using auto-
matic edge detection software (Information Integrity).assessing its short-term effect on NO-dependent endo-
Analysis was performed by an experienced vascular tech-thelial function in conduit and resistance arteries.
nician blinded to the subject and order and repeated by
a second investigator in a random selection of one third
METHODS of scans (studies where dilatation differed by 1% were
Subjects deemed technically inadequate). Using pulsed-wave Dop-
pler, blood flow was recorded continuously throughoutThe study population included 17 subjects (12 male)
the study and was expressed as the velocity time integralreceiving hemodialysis for a minimum of 3 months, 33
(VTI), the area under the blood velocity/time curve forsubjects (19 male) with severe chronic renal failure not
a complete cardiac cycle. Baseline recordings of arterialyet receiving renal replacement therapy [glomerular fil-
diameter were made for 1 minute before inflation of atration rate (GFR) 20 mL/min, estimated from plasma
blood pressure cuff placed distal to the site of arterialcreatinine using the Cockcroft-Gault formula], and a
imaging. Recording continued for 5 minutes during cuffcontrol group of eight healthy volunteers recruited from
inflation to 300 mm Hg and for 4 minutes after deflation.hospital staff. Patients were excluded if they were 70
Endothelium-independent dilatation was assessed by
years of age, were current smokers, or if they had diabe- measuring the dilator response to a submaximal dose of
tes or a fasting cholesterol of 6 mmol/L (recognized the NO donor, glyceryltrinitrate (GTN), 25 g sublin-
independent risk factors for endothelial dysfunction). gually. This elicited vascular dilatation of the same order
Nitrates and angiotensin-converting enzyme (ACE) in- of magnitude as that of the endothelium-dependent flow
hibitors were discontinued 48 hours before study and stimulus (larger doses of GTN may fail to allow discrimi-
antioxidant vitamin supplements 4 weeks before study. nation between subtle differences of intrinsic smooth
All other regular medications were continued. The proj- muscle reactivity).
ect was approved by local hospital Research Ethics Com-
Protocol 1: The effect of intra-arterial vitamin C onmittees.
resistance artery endothelial function in subjects
Assessment of forearm blood flow with predialysis renal failure
(resistance vessel function) Sixteen subjects (nine male) approaching end-stage
Mercury-in-Silastic strain-gauge plethysmography was renal failure (ESRF) (calculated GFR 20 mL/min)
were recruited. Forearm blood flow responses were mea-used to measure forearm blood flow (mL/100 mL fore-
sured during intrabrachial infusion of the endothelium-arm/minute) in both arms as described previously [16].
dependent vasodilator acetylcholine (ACh), at 25, 50,For each study, the brachial artery of the nondominant
and 100 nmol/min. Each dose was given for 3 minutesarm was cannulated with a 27-gauge needle (Cooper’s
(N  16) followed 15 minutes later by the endothelium-Needle Works, Birmingham, England, UK) inserted un-
independent dilatator GTN, at 4, 8, and 16 nmol/min,der local anesthesia (2 mL 1% lignocaine). Drug or saline
each given for 5 minutes (N  10), or sodium nitroprus-(sodium chloride 0.9% wt/vol) were infused continuously
side (SNP) at 4, 8, and 16 nmol/min, each given for 5at 0.5 mL/min. During recording periods, the hands were
minutes (N  6). After a further 15 minutes (to allowexcluded from the circulation by inflation of wrist cuffs
baseline flow to be reestablished), vitamin C (25 mg/to 200 mm Hg [17].
min) was infused via the brachial artery and the dilator
response to ACh and GTN or SNP were determined asAssessment of conduit artery endothelial function
above.Endothelial function was determined by recording the
dilator response of the brachial or radial artery to in- Protocol 2: The effect of intra-arterial vitamin C
creased blood flow generated during reactive hyperemia on resistance vessel endothelial function in
of the downstream forearm (brachial artery studies) or healthy volunteers
hand (radial artery studies). Subjects lay supine in a The effect of intra-arterial vitamin C on endothelial
temperature-controlled laboratory (22 to 25C). The bra- function in healthy volunteers was determined. Re-
chial or radial arteries of the nonfistula or nondominant sponses to ACh and GTN were measured before and
arm were scanned in longitudinal section using a 7 MHz after infusion of vitamin C (as in protocol 1).
linear array transducer and an XP 128/10 (Acuson, Er-
Protocol 3: The effect of NO synthase inhibitionlangen, Germany), magnified using a resolution box
on endothelial function in the presence andfunction and gated with the R wave of the electrocardio-
absence of vitamin Cgram (ECG). End-diastolic images of the vessels were
acquired every 3 seconds using data-acquisition software This protocol examined the effect of vitamin C on
(Information Integrity, Boston, MA, USA) and stored ACh-mediated dilatation in eight predialysis subjects be-
fore and after inhibition of NO synthase with NG mono-off-line for later analysis. Arterial diameter over a 1 to
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methyl-l-arginine (L-NMMA). Forearm blood flow re- Ethylenediaminetetraacetic acid (EDTA) and lithium-
heparin samples were placed on ice immediately aftersponses to ACh (25, 50, and 100 nmol/min) were deter-
mined. After 15 minutes washout, L-NMMA (4 mol/ sampling. Serum samples were allowed to clot at room
temperature for 10 minutes. Samples were centrifugedmin) was infused and 10 minutes later, the effect of ACh
was reassessed in the presence of L-NMMA. After a within 30 minutes of collection at 4500 rpm, 4C for
15 minutes. Duplicates were collected to assess analysisfurther 15 minutes, vitamin C (25 mg/min) was coinfused
with L-NMMA for 10 minutes, after which the response reproducibility. After individual preparation, all samples
were stored at 80C.to ACh was measured in the presence of both L-NMMA
and vitamin C.
Total antioxidant capacity
Protocol 4: The effect of vitamin C on conduit artery Using 200 L serum, total antioxidant capacity was
endothelial function in subjects with predialysis determined by an enhanced chemiluminescence method
renal failure [18]. This method depends on the continuous production
of a free radical–mediated luminescent light signal.In ten subjects, (six male) the brachial artery was can-
nulated to allow infusion of vitamin C into the down- When a sample containing antioxidants is added, the
light signal is temporarily stopped by its free radical–stream radial artery. Radial flow-mediated dilatation
(FMD) and radial dilatation to GTN were measured scavenging action. The time taken for the light signal to
return is then directly proportional to the amount ofduring saline infusion and 15 minutes later in the pres-
ence of vitamin C (25 mg/min; preinfused for 15 minutes). antioxidant in the sample.
Vitamin C concentrationProtocol 5: The effect of systemic vitamin C on
conduit artery endothelial function in subjects To determine vitamin C concentrations, 500 L serum
with end-stage renal failure was immediately deproteinized with 500 L freshly pre-
pared 10% wt/vol metaphosphoric acid. The sample wasBecause of ethical concerns about arterial cannulation
of hemodialysis patients, vitamin C was administered by then centrifuged for a further 5 minutes at 4500 rpm and
the supernatant separated. Concentrations of vitaminintravenous infusion and endothelial function assessed
by measuring FMD of the brachial artery. FMD was C was determined by reverse-phase high-performance
liquid chromatography (HPLC) using ultraviolet detec-assessed in 17 patients before and after administration
of vitamin C in a randomized double-blind placebo con- tion at wavelengths of 292 nm [19, 20].
trolled crossover design. Patients were assigned to re-
Total glutathione levels (whole blood and plasma)ceive either vitamin C (3 g in 100 mL 0.9% saline over
10 minutes) or placebo (100 mL 0.9% saline over 10 To quantify total (oxidized and reduced) plasma gluta-
thione, 1 mL EDTA plasma was immediately depro-minutes) intravenously and crossed over to the other
intervention on the second visit. Each patient was exam- teinzed with 60 L 30% perchloric acid. Samples were
centrifuged for a further 5 minutes and the supernatantined immediately before hemodialysis on two occasions
1 week apart. On each occasion, FMD and GTN-induced separated; whole blood was collected in EDTA. Whole
blood and plasma glutathione was determined by enzymedilatation (separated by 5 minutes) were measured at
baseline and 20 minutes after completion of the intrave- rate assay using the colorimetric dye 5,5-dithio-bis(2-nitro-
benzoic) acid (DTNB) [21]. This method relies on thenous infusion. Blood pressure and pulse rate were re-
corded before and after each scan using the nonstudy recycling of the oxidized and reduced forms of glutathi-
one by the enzyme glutathione reductase, determinedarm or the calf (in the presence of a fistula) with an
automated oscillometric system (Dinamap Vital Signs by spectrophotometry at a wavelength of 412 nm.
Monitor 1846 8X; Critikon, Tampa, FL).
Total lipid hydroperoxides
Biochemical measurements Lipid hydroperoxides were analyzed spectrophoto-
metrically by the ferrous oxidation of the colorimetric dyeBaseline measures of total fasting cholesterol, lipid
subfractions, urea, creatinine, potassium and C-reactive xylenol orange (FOX 2) at a wavelength of 560 nm in con-
junction with the specific hydroperoxide reductant triphe-protein (CRP) were made.
nylphosphine using 500 L lithium-heparin plasma [22].
Measures of oxidant stress
Calculations and statisticsBlood samples were taken before and during intra-
arterial infusion of vitamin C from an ipsilateral antecu- Data are presented as mean  SEM unless otherwise
stated. For venous occlusion plethysmography studiesbital vein (protocol 4) and before and 20 minutes after
completion of the intravenous infusion of vitamin C or (protocols 1 to 3), mean blood flow for the last 60 seconds
of each infused dose was expressed as mL/100 mL fore-placebo (protocol 5) for assessment of oxidative stress.
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Table 1. Subject characteristics
Mean (SEM) ESRF PDRF Healthy volunteers
Number (male) 17 (9) 33 (19) 8 (5)
Age years 373 394 414
GFR mL/min ESRF 176 1104
Systolic blood pressure mm Hg 1719 148.89.8 1376
Diastolic blood pressure mm Hg 844 815 796
MAP mm Hg 1136 1039 1016
Cholesterol mmol/L 4.10.2 4.00.3 4.20.3
Triglycerides mmol/L 1.70.2 1.50.2 1.30.3
Low-density lipoprotein cholesterol 2.50.1 2.70.3 2.60.1
High-density lipoprotein cholesterol 1.20.07 1.10.1 1.40.1
C-reactive protein 12.14.8 8.21.5 4.81.2
Hemoglobin gm/dL 10.10.2 11.40.4 12.50.3
Potassium lmol/L 5.30.3 4.50.2 3.70.2
Abbreviations are: ESRF, end-stage renal failure; PDRF, predialysis renal failure; GFR, glomerular filtration rate; MAP, mean arterial pressure.
Table 2. The effect of parenteral vitamin C on basal cardiovascular measures
Pre-dialysis (radial artery) Protocol 4 ESRF (brachial artery) Protocol 5
Before intra-arterial After intra-arterial Before intravenous After intravenous
vitamin C vitamin C vitamin C vitamin C
Mean arterial pressure mm Hg 1052.7 1052.4 1136 1166
Pulse bpm 704 684 794 783
Baseline arterial diameter mm 2.60.1 2.60.1 4.10.2 4.10.2
ESRF is end-stage renal failure.
Table 3. The effect of intra-arterial vitamin C on basal forearmarm volume/minute. For conduit vessel responses (proto-
blood flow
cols 4 and 5), flow stimulus during reactive hyperemia
Predialysis (resistance vessels)was measured 5 seconds after cuff release and subse- Baseline forearm blood flow
mL/100 mL forearm/minute Previtamin C Postvitamin C P valuequently at 15-second intervals for 90 seconds. Dilatation
was expressed as the percentage change from baseline Protocol 1 3.61.1 4.21.0 0.1
Protocol 2 3.90.7 4.70.9 0.2diameter of the brachial or radial artery and analyzed
Protocol 3 (L-NMMA) 1.90.3 2.20.8 0.6by comparing both the maximal dilatation (mean of three
L-NMMA is NGmonomethyl-l-arginine.consecutive observations) and the area under the curve
of dilatation against time (AUC) (units % time). Data
were compared using two-tailed Student t test or analysis
37% calcium channel blockers, 24% ACE inhibitors, andof variance of repeated measures as appropriate where
19% potassium channel openers). Blood pressure andP  0.05 was considered significant (Graph Pad Prism,
pulse rate were unaffected by intra-arterial or intrave-San Diego, CA, USA). The study had 90% power to
nous infusion of vitamin C (Table 2). Blood flow indetect intraindividual differences of 1% in FMD, based
the noninfused arm (plethysmography studies) did noton the standard deviation observed in studies of repeated
change during the experiments (data not shown). Intra-baseline measures within individuals performed by our
arterial vitamin C caused a small increase in baseline
group (unpublished observations). forearm blood flow in all groups (protocols 1 to 3), how-
ever, this did not reach statistical significance (Table 3).
Baseline arterial diameters in both conduit artery studiesRESULTS
(protocols 4 and 5) were unchanged by vitamin C infu-
The study population characteristics for the hemodial- sion (Table 2).
ysis, predialysis, and control groups are detailed in Table
1. The dialysis-dependent group was receiving an aver- Effect of vitamin C on resistance vessel
endothelial functionage of 1.6 antihypertensive agents (24% 	 blockers, 35%

 blockers, 41% calcium channel blockers, 29% ACE In patients with predialysis renal failure, vitamin C
inhibitors, and 22% potassium channel openers) com- increased the dilator response to ACh (Fig. 1A; P 
pared with an average of 1.4 antihypertensive agents in 0.01; N  16), but did not alter the response to GTN
(Fig. 1B; P  0.6; N  10) or SNP (Fig. 1C; P  0.3;the predialysis group (28% 	 blockers, 39% 
 blockers,
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Fig. 1. The effect of intra-arterial infusion of vitamin C on vascular function in subjects with predialysis renal failure. Resistance vessel responses
to the endothelium-dependent dilator acetylcholine (A), endothelium-independent dilators glyceryltrinitrate (GTN) (B), and sodium nitroprusside
(SNP) (C). Symbols are () before vitamin C; () after vitamin C.
Fig. 2. The effect of vitamin C on vascular
function in healthy volunteers. (A) The effect
of intra-arterial vitamin C on resistance vessel
responses to the endothelium dependent-dila-
tor acetylcholine (ACh). Symbols are () be-
fore vitamin C; () after vitamin C. (B) The
effect of intra-arterial vitamin C on the endo-
thelium independent-dilator glyceryltrinitrate
(GTN). Symbols are () before vitamin C;
() after vitamin C.
N  6). In contrast, vitamin C had no effect on the Effect of vitamin C on radial artery
endothelial functiondilator response to ACh (Fig. 2A; P  0.7; N  8), or
GTN (Fig. 2B; P  0.9; N  8) in healthy volunteers. In patients with predialysis renal failure, intra-arterial
L-NMMA reduced basal forearm blood flow in pre- vitamin C did not alter the flow stimulus during reactive
dialysis patients (3.0  0.48 mL/100 mL forearm/minute hyperemia of the hand (peak VTI before 0.24  0.1 m
before vs. 1.3  0.36 mL/ 100 mL forearm/minute after vs. 0.25  0.1 m after vitamin C; P  0.4; flow envelope
L-NMMA; P  0.03; N  8) and the dilatation to ACh before 12.9  1.5 msec vs. 12.7  1.7 msec after vitamin
(Fig. 3) [P  0.002 by analysis of variance (ANOVA)]. C; P  0.6; N  10, Fig. 4A). Vitamin C did not increase
In the presence of L-NMMA, infusion of vitamin C did radial FMD (6.1  0.8% before and 6.0  1.0% after
not increase the dilator response to ACh (Fig. 3; P  vitamin C; N  10; ANOVA P  0.8; Fig. 4B) or the
AUC (640.0  33.1% seconds before vs. 639.5  39.0%0.05; N  8).
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min C or placebo (5.7  1.4% before vs. 5.6  1.4%
after vitamin C; 6.5  1.5% before vs. 6.2  1.3% after
placebo; ANOVA of four groups P  0.5; Fig. 5F).
The effect of vitamin C on markers of oxidative stress
Intrarterial infusion of 25 mg/min vitamin C resulted
in a 100-fold increase in plasma vitamin C in the venous
effluent of the infused arm (25.6  3.3 mol/L before
vs. 2910.5  303.9 mol/L after; N  10; P  0.00001)
and total antioxidant capacity (459.5  34.1 mol/L be-
fore vs. 5582.1  495.5 mol/L Trolox equivalence (Eq)
after; P  0.0001; N  10). However, whole blood gluta-
thione levels were unaffected (533.3  74.3 mol/L be-
fore and 532.2  75.4 mol/L after; P  0.6; N  10).
Intravenous infusion of 3 g vitamin C resulted in an
approximately 4.5-fold increase in plasma concentration
(44.1  4.5 mol/L before vs. 201  20.1 mol/L after;
N  17; P  0.0001). There were similar increases in
total antioxidant capacity (496.4  20.4 mol/L before
vs. 1223.5  75.9 mol/L Trolox Eq after vitamin C;
N  17; P  0.0001). Whole blood and plasma glutathi-Fig. 3. The effect of intra-arterial NGmonomethyl-L-arginine (L-NMMA)
on the augmented dilator response to acetylcholine (ACh) in the pres- one levels were unaffected by intravenous vitamin C,
ence of vitamin C. Symbols are: (), Acetylcholine; () L-NMMA; (whole blood oxidized glutathione was 404.8  25.8
() L-NMMA and vitamin C.
mol/L before vs. 391.3  77.1 mol/L after; N  17;
P  0.5) (plasma oxidized glutathione was 0.31  0.19
mol/L before and 0.24  0.08 mol/L after; N  17;
seconds after vitamin C; P  0.8; N  10; Fig. 4C). P 0.2). In contrast, vitamin C increased lipid hydroper-
Similarly, the response to GTN was unaffected by vita- oxides (11.0  1.7 mol/L before vs. 14.7  1.8 mol/L
min C infusion (8.1  1.5% before vs. 8.5  0.4% after after vitamin C; P  0.01; N  17). These indices of
vitamin C; P  0.6; Fig. 4B). oxidant stress were unaffected by placebo (Table 4).
Effect of vitamin C on brachial artery endothelial
DISCUSSIONfunction in patients with dialysis-dependent
renal failure This study demonstrates that acute administration of
vitamin C increases endothelium-dependent dilatationIntravenous vitamin C did not alter the flow stimulus
in the resistance vasculature of patients with predialysisduring reactive hyperemia of the forearm (peak VTI
renal failure. This effect is NO-dependent because it isbefore 0.28  0.02 m vs. 0.28  0.03 m after vitamin C;
abolished in the presence of the NO synthase inhibitorP 0.9; flow envelope 14.2 1.2 msec before and 13.5
L-NMMA. In contrast, vitamin C did not alter endothe-1.2 msec after vitamin C; ANOVA P  0.5; N  17, Fig.
lium-dependent dilatation in peripheral conduit vessels5A). The flow stimuli before vs. after placebo were also
of either predialysis patients or patients with dialysis-similar (peak VTI before 0.32  0.02 m vs. 0.34  0.03
dependent renal failure. Vitamin C had no effect onm after; P  0.1, flow envelope before 15.1  1.2 msec
endothelium-independent dilatation to GTN or SNP.vs. 15.1  1.2 msec after vitamin C; ANOVA P  0.9;
These observations suggest that in renal failure, oxida-N  17, Fig. 5B).
tive stress is a short-term determinant of resistance (butFMD of the brachial artery was unaffected by vitamin
not conduit) artery endothelial function by modulatingC (4.3  0.9% before vs. 3.7  1.0% after vitamin C;
the activity of the NO pathway.P  0.3; N  17; Fig. 5C) or placebo (4.0  1.1% before
Endothelial dysfunction has been consistently demon-vs. 3.3 0.9% after; P 0.2; N 17; Fig. 5C). Similarly,
strated in conduit vessels of patients with renal failurethe AUC before and after intravenous vitamin C or
[23–27], with a smaller defect seen in the resistance vas-placebo remained unchanged (587.4  108.4% seconds
culature [28, 29]. Increased oxidative stress may contrib-before vs. 500.1  89.6% seconds after vitamin C; P 
ute to endothelial dysfunction in these patients. Sources0.2; N  17; Fig. 5D; 594.2  128.5% seconds before vs.
of oxidative stress in renal failure include hyperhomocys-420.1  71.4% seconds after placebo; P  0.2; N  17;
teinaemia [30], anemia (and treatment with intravenousFig. 5E; ANOVA of four groups P  0.4).
Response to GTN was also unaffected by either vita- iron or erythropoietin) [31] and dialysis membrane bio-
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Fig. 4. The effect of intra-arterial vitamin C on conduit artery endothelial function in predialysis renal failure. (A) The velocity time integral
(VTI) before () and after () intra-arterial vitamin C infusion. (B) Radial flow-mediated dilatation (FMD) and dilatation to the endothelium
independent dilator, glyceryltrinitrate (GTN). (C) The profile of radial FMD for the 5-minute period after cuff release. Symbols are () before
vitamin C; () after vitamin C.
Fig. 5. The effect of intravenous vitamin C on conduit artery endothelial function in dialysis dependent renal failure. (A) The velocity time integral
(VTI) before () and after () intravenous vitamin C. (B) The velocity time integral (VTI) before () and after () intravenous placebo. (C)
The effect of intravenous vitamin C on brachial flow-mediated dilatation (FMD). (D) The profile of brachial FMD for the 5-minute period after
cuff release is shown before () and after () vitamin C. (E) The profile of brachial FMD for the 5-minute period after cuff release is shown
before () and after () placebo. (F ) ilatation to glyceryltrinitrate (GTN).
incompatibility (causing recurrent leukocyte activation). low dietary intake and increased plasma clearance during
dialysis) [32], reduced glutathione [33] and reduced activ-In addition to increased production of ROS, antioxidant
defense systems are deficient in renal disease, with low itiy of the antioxidant enzymes superoxide dismutase,
catalase, and glutathione peroxidase [34]. Consistentplasma concentrations of antioxidant vitamins (due to
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with a role for oxidative stress in endothelial dysfunction
and increased cardiovascular risk in renal failure [35],
administration of antioxidants in hemodialysis patients
with preexisting cardiovascular disease improves cardio-
vascular outcome [15].
Vitamin C has been used as an experimental tool in the
investigation of the functional consequences of oxidant
stress in the human cardiovascular system. In the present
study, administration of vitamin C into the forearm of
predialysis patients increased dilatation to the endothe-
lium-dependent dilator ACh, but had no effect on the
response to either GTN or SNP, indicating a specific
effect on the vascular endothelium. L-NMMA reduced
dilatation to ACh in patients with predialysis renal fail-
ure, implicating NO in the dilator mechanism of ACh
in patients with renal failure. Furthermore, L-NMMA
abolished the effect of vitamin C to augment the re-
sponse to ACh, indicating that its action is NO-depen-
dent. This finding suggests that the action of vitamin C
is to promote the bioactivity of endogenous NO rather
than an action on other endothelium-derived mediators
(such as prostacyclin or endothelial hyperpolarizing fac-
tor [EDHF]). These results are consistent with studies
in other cardiovascular risk groups in which infusions
of vitamin C have increased dilatation of the resistance
vasculature to ACh [3, 5, 36]. Vitamin C had no effect
in healthy controls, which implies that under physiologic
conditions, oxidative stress has little role in determining
NO bioavailability (either NO synthesis and release, or
stability of NO postsynthesis).
In contrast, vitamin C (despite 100-fold elevations in
local concentration) had little effect on conduit artery
function in either dialysis or predialysis patients, despite
the presence of high levels of oxidative stress in this
group [33, 37]. In dialysis patients, we chose to administer
vitamin C intravenously using a protocol that has been
demonstrated both to reduce measures of oxidative
stress and improve conduit artery endothelial function
[38], in hyperhomocysteinemia [39], hypertension [6],
and hypercholesterolemia [5]. Our findings suggest that
in renal failure, oxidative stress is not a major determi-
nant of conduit artery endothelial function.
It is not clear why conduit and resistance vessels differ
in their response to vitamin C. Antioxidants, including
vitamin C, may also have pro-oxidant properties [40–42],
particularly in the presence of transition metal ions. This
interaction between high doses of ascorbic acid and re-
dox active metal ions such as iron might offset any effect
to promote NO activity, and this balance might be differ-
ent in conduit and resistance vessels. Our biochemical
measures of oxidative stress indicated a complex picture
after administration of vitamin C. Both total antioxidant
activity and vitamin C concentration increased after vita-
min C administration, whole blood, and plasma glutathi-
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